Abstract: The disclosure provides a cranial rotation system, including a subject stage configured to support a subject; a cranial support configured to support a cranium of the subject and rotate relative to the subject stage; subject stage a motor configured to rotate the cranial support about a rotational axis; and a controller configured to operate the motor.

Abstract: A system and method for monitoring a motor of a vehicle system monitor operating conditions of the vehicle system and determine whether the operating conditions of the vehicle system match designated operating conditions. Responsive to determining that the operating conditions of the vehicle system that are monitored match the designated operating conditions, an electrical signature representative of an electric current supplied to the motor of the vehicle system is examined and damage to one or more of the motor of the vehicle system or a mechanical coupling of the motor to one or more of a wheel or axle of the vehicle system is identified based on the electrical signature that is examined.

Abstract: The disclosure provides a cranial rotation system, including a subject stage configured to support a subject; a cranial support configured to support a cranium of the subject and rotate relative to the subject stage; subject stage a motor configured to rotate the cranial support about a rotational axis; and a controller configured to operate the motor.

Abstract: A system and method for monitoring a motor of a vehicle system monitor operating conditions of the vehicle system and determine whether the operating conditions of the vehicle system match designated operating conditions. Responsive to determining that the operating conditions of the vehicle system that are monitored match the designated operating conditions, an electrical signature representative of an electric current supplied to the motor of the vehicle system is examined and damage to one or more of the motor of the vehicle system or a mechanical coupling of the motor to one or more of a wheel or axle of the vehicle system is identified based on the electrical signature that is examined.

Abstract: A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1-R8 is a sulfonic acid, a carboxylic acid, a phosphonic acid, a pharmaceutically acceptable salt of a sulfonic acid, a pharmaceutically acceptable salt of a carboxylic acid, a pharmaceutically acceptable salt of a phosphonic acid, a sulfonate ester, a carboxylate acid ester, or a phosphonate ester; and the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocycl

Abstract: An improved heat engine that includes an organic refrigerant exhibiting a boiling point below ?35° C.; a heat source having a temperature of less than 82° C.; a heat sink; a sealed, closed-loop path for the organic refrigerant, the sealed, closed-loop path having both a high-pressure zone that absorbs heat from the heat source, and a low-pressure zone that transfers heat to the heat sink; a positive-displacement decompressor providing a pressure gradient through which the organic refrigerant in the gaseous phase flows continuously from the high-pressure zone to the low-pressure zone, the positive-displacement decompressor extracting mechanical energy due to the pressure gradient; and a positive-displacement hydraulic pump, which provides continuous flow of the organic refrigerant in the liquid phase from the low-pressure zone to the high-pressure zone, the hydraulic pump and the positive-displacement decompressor maintaining a pressure differential between the two zones of between about 20 to 42 bar.

Abstract: Disclosed herein are system, method, and computer program product embodiments for introducing and removing blockchain based cryptocurrency tokens based on usage and demand for the cryptocurrency. An embodiment operates by transmitting, to a peer-to-peer network of computing devices configured to store a blockchain of processes, instructions for execution by one or more devices of the peer-to-peer network. The instructions comprise determining a rate of change associated with an exchange price of a cryptocurrency token. The instructions further include receiving an indication that a first amount of cryptocurrency tokens has been transferred to a recipient address of a plurality of addresses and generating a second amount of cryptocurrency tokens based on the first amount of cryptocurrency tokens that has been transferred and on the determined rate of change of the exchange price associated with the cryptocurrency token. The second amount of cryptocurrency tokens is allocated to the recipient address.

Abstract: An improved heat engine that includes an organic refrigerant exhibiting a boiling point below ?35° C.; a heat source having a temperature of less than 82° C.; a heat sink; a sealed, closed-loop path for the organic refrigerant, the sealed, closed-loop path having both a high-pressure zone that absorbs heat from the heat source, and a low-pressure zone that transfers heat to the heat sink; a positive-displacement decompressor providing a pressure gradient through which the organic refrigerant in the gaseous phase flows continuously from the high-pressure zone to the low-pressure zone, the positive-displacement decompressor extracting mechanical energy due to the pressure gradient; and a positive-displacement hydraulic pump, which provides continuous flow of the organic refrigerant in the liquid phase from the low-pressure zone to the high-pressure zone, the hydraulic pump and the positive-displacement decompressor maintaining a pressure differential between the two zones of between about 20 to 42 bar.

Abstract: An improved heat engine that includes an organic refrigerant exhibiting a boiling point below ?35° C.; a heat source having a temperature of less than 82° C.; a heat sink; a sealed, closed-loop path for the organic refrigerant, the sealed, closed-loop path having both a high-pressure zone that absorbs heat from the heat source, and a low-pressure zone that transfers heat to the heat sink; a positive-displacement decompressor providing a pressure gradient through which the organic refrigerant in the gaseous phase flows continuously from the high-pressure zone to the low-pressure zone, the positive-displacement decompressor extracting mechanical energy due to the pressure gradient; and a positive-displacement hydraulic pump, which provides continuous flow of the organic refrigerant in the liquid phase from the low-pressure zone to the high-pressure zone, the hydraulic pump and the positive-displacement decompressor maintaining a pressure differential between the two zones of between about 20 to 42 bar.

Abstract: A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1-R8 is a sulfonic acid, a carboxylic acid, a phosphonic acid, a pharmaceutically acceptable salt of a sulfonic acid, a pharmaceutically acceptable salt of a carboxylic acid, a pharmaceutically acceptable salt of a phosphonic acid, a sulfonate ester, a carboxylate acid ester, or a phosphonate ester; and the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocycl

Abstract: A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1-R8 is a sulfonic acid, a carboxylic acid, a phosphonic acid, a pharmaceutically acceptable salt of a sulfonic acid, a pharmaceutically acceptable salt of a carboxylic acid, a pharmaceutically acceptable salt of a phosphonic acid, a sulfonate ester, a carboxylate acid ester, or a phosphonate ester; and the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocycl

Abstract: A system and method for monitoring a motor of a vehicle system monitor operating conditions of the vehicle system and determine whether the operating conditions of the vehicle system match designated operating conditions. Responsive to determining that the operating conditions of the vehicle system that are monitored match the designated operating conditions, an electrical signature representative of an electric current supplied to the motor of the vehicle system is examined and damage to one or more of the motor of the vehicle system or a mechanical coupling of the motor to one or more of a wheel or axle of the vehicle system is identified based on the electrical signature that is examined.

Abstract: An improved heat engine that includes an organic refrigerant exhibiting a boiling point below ?35° C.; a heat source having a temperature of less than 82° C.; a heat sink; a sealed, closed-loop path for the organic refrigerant, the sealed, closed-loop path having both a high-pressure zone that absorbs heat from the heat source, and a low-pressure zone that transfers heat to the heat sink; a positive-displacement decompressor providing a pressure gradient through which the organic refrigerant in the gaseous phase flows continuously from the high-pressure zone to the low-pressure zone, the positive-displacement decompressor extracting mechanical energy due to the pressure gradient; and a positive-displacement hydraulic pump, which provides continuous flow of the organic refrigerant in the liquid phase from the low-pressure zone to the high-pressure zone, the hydraulic pump and the positive-displacement decompressor maintaining a pressure differential between the two zones of between about 20 to 42 bar.

Abstract: A method of treating a cellular injury in a subject comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of formula I: wherein at least one of R1-R8 is a sulfonic acid, a carboxylic acid, a phosphonic acid, a pharmaceutically acceptable salt of a sulfonic acid, a pharmaceutically acceptable salt of a carboxylic acid, a pharmaceutically acceptable salt of a phosphonic acid, a sulfonate ester, a carboxylate acid ester, or a phosphonate ester; and the remaining R1-R8 are each independently selected from hydrogen, halo, hydroxyl, nitro, nitroso, amino, substituted amino, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, alkoxy, substituted alkoy, alkenyloxy, substituted alkenyloxy, alkynyloxy, substituted alkynyloxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkynyl, substituted cycloalkynyl, cycloalkyloxy, substituted cycloalkyloxy, heterocyclyl, substituted heterocyclyl, heterocyclyl

Abstract: Methods and compositions for reducing, preventing or reversing organ damage and/or enhancing organ preservation by administration of a peroxisome-proliferator activated receptor-alpha (PPAR?) agonist to the organ.

Abstract: The disclosed system enables a sender to ship an item in an envelope using a mobile shipping application running on a computing device or carrier computer. This system includes an electronic envelope having an updateable flexible electronic visual display that displays shipping information transmitted by a carrier computer via a wireless network, a cellular chip for receiving updated shipping information from the carrier computer, and a microcomputer chip for transmitting the information to the electronic display. The computing device, carrier computer, or both, execute the mobile shipping application that is accessible with a computing device and through which a sender places a shipping order. The system further comprises a carrier computer configured to execute the mobile shipping application running on the carrier computer, a data storage device to store the shipping orders, and a transceiver for communicating with the cellular chip on the envelope across a wireless communications network.

Abstract: The disclosed system enables a sender to ship an item in an envelope using a mobile shipping application running on a computing device or carrier computer. This system includes an electronic envelope having an updateable flexible electronic visual display that displays shipping information transmitted by a carrier computer via a wireless network, a cellular chip for receiving updated shipping information from the carrier computer, and a microcomputer chip for transmitting the information to the electronic display. The computing device, carrier computer, or both, execute the mobile shipping application that is accessible with a computing device and through which a sender places a shipping order. The system further comprises a carrier computer configured to execute the mobile shipping application running on the carrier computer, a data storage device to store the shipping orders, and a transceiver for communicating with the cellular chip on the envelope across a wireless communications network.

Abstract: Methods and compositions for reducing, preventing or reversing organ damage and/or enhancing organ preservation by administration of a peroxisome-proliferator activated receptor-alpha (PPAR?) agonist to the organ.